Compare Gilead Sciences, Inc. (GILD) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Shopify Inc. — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Shopify Inc. trades at $165.78 (market cap $211.73B). The key difference: Shopify Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Shopify Inc. for 78 Days on average.
| GILD | SHOP | |
|---|---|---|
Market Cap | $182.40B | $211.73B |
Volume | 4,469,821 | 7,146,651 |
Sector | Health | Technology |
52-Week High | $155.80 | $179.01 |
52-Week Low | $116.74 | $95.40 |
Typical Hold Time | 111 Days | 78 Days |
Enterprise Value | $205.46B | $206.96B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
SHOP trades at $165.94, up 0.88% with strong bullish momentum near its consensus price target of $168.63. The stock shows robust revenue growth from $5.6B in 2022 to $11.6B in 2025, with net income turning positive to $1.23B. Technical indicators show bullish moving averages but overbought RSI levels, while fundamental valuation remains elevated with P/E of 111.19. Recent developments include Shopify's AI-powered Canvas platform launch and strategic positioning in the AI commerce space.
Outlook remains positive with 67% analyst buy ratings and projected revenue growth to $13.3B in 2026. Key opportunities include merchant solutions growth and AI integration, while risks include high valuation multiples and competitive pressures from Amazon. The stock presents growth potential but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
